Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) EBITDA Margin (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of EBITDA Margin data on record, last reported at 1527.57% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 47576.0% year-over-year to 1527.57%; the TTM value through Dec 2025 reached 823.03%, down 11867.0%, while the annual FY2025 figure was 823.03%, 11863.0% down from the prior year.
  • EBITDA Margin reached 1527.57% in Q4 2025 per ACRS's latest filing, down from 439.5% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 2.66% in Q4 2023 and bottomed at 1622.58% in Q2 2023.
  • Average EBITDA Margin over 5 years is 889.3%, with a median of 1005.84% recorded in 2021.
  • The widest YoY moves for EBITDA Margin: up 122182bps in 2024, down -104914bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 1533.98% in 2021, then skyrocketed by 77bps to 349.12% in 2022, then surged by 99bps to 2.66% in 2023, then tumbled by -39388bps to 1051.81% in 2024, then plummeted by -45bps to 1527.57% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 1527.57% in Q4 2025, 439.5% in Q3 2025, and 865.56% in Q2 2025.